NCT00396279View on ClinicalTrials.gov

Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 10, 2006

Primary Completion Date

April 7, 2008

Study Completion Date

February 1, 2011

Conditions
GCTGiant Cell Tumor of Bone
Interventions
BIOLOGICAL

Denosumab

Administered by subcutaneous injection

DIETARY_SUPPLEMENT

Calcium/Vitamin D

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY